BMF 500
Alternative Names: BMF-500Latest Information Update: 19 Jun 2025
At a glance
- Originator Biomea Fusion
- Class Antineoplastics; Small molecules
- Mechanism of Action Fms-like tyrosine kinase 3 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Acute biphenotypic leukaemia; Acute myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 13 Jun 2025 Updated pharmacokinetics, pharmacodynamics, efficacy and adverse events data from a phase I COVALENT-103 trial in Acute myeloid leukaemia released by Biomea Fusion
- 14 May 2025 Pharmacokinetics, pharmacodynamics, efficacy and adverse events data from a phase I trial in Acute myeloid leukaemia released by Biomea Fusion
- 09 Dec 2024 Pharmacokinetics, pharmacodynamics, efficacy and adverse events data from a phase I trial in Acute myeloid leukaemia released by Biomea Fusion